IL259297B2 - Heterocyclic compounds for the treatment of disease - Google Patents

Heterocyclic compounds for the treatment of disease

Info

Publication number
IL259297B2
IL259297B2 IL259297A IL25929718A IL259297B2 IL 259297 B2 IL259297 B2 IL 259297B2 IL 259297 A IL259297 A IL 259297A IL 25929718 A IL25929718 A IL 25929718A IL 259297 B2 IL259297 B2 IL 259297B2
Authority
IL
Israel
Prior art keywords
optionally substituted
compound
formula
another embodiment
group
Prior art date
Application number
IL259297A
Other languages
English (en)
Hebrew (he)
Other versions
IL259297B (en
IL259297A (en
Original Assignee
Oppilan Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oppilan Pharma Ltd filed Critical Oppilan Pharma Ltd
Publication of IL259297A publication Critical patent/IL259297A/en
Publication of IL259297B publication Critical patent/IL259297B/en
Publication of IL259297B2 publication Critical patent/IL259297B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL259297A 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease IL259297B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562255041P 2015-11-13 2015-11-13
PCT/US2016/061676 WO2017083756A1 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Publications (3)

Publication Number Publication Date
IL259297A IL259297A (en) 2018-07-31
IL259297B IL259297B (en) 2022-11-01
IL259297B2 true IL259297B2 (en) 2023-03-01

Family

ID=58696139

Family Applications (1)

Application Number Title Priority Date Filing Date
IL259297A IL259297B2 (en) 2015-11-13 2016-11-11 Heterocyclic compounds for the treatment of disease

Country Status (22)

Country Link
US (5) US10683291B2 (enExample)
EP (2) EP4163281B1 (enExample)
JP (3) JP6933384B2 (enExample)
KR (1) KR102720397B1 (enExample)
CN (2) CN114149424B (enExample)
AU (2) AU2016353348A1 (enExample)
BR (1) BR112018009745B1 (enExample)
CA (1) CA3005236C (enExample)
DK (1) DK3373931T3 (enExample)
ES (1) ES2932049T3 (enExample)
HR (1) HRP20221417T1 (enExample)
HU (1) HUE060594T2 (enExample)
IL (1) IL259297B2 (enExample)
LT (1) LT3373931T (enExample)
MX (1) MX382092B (enExample)
PL (1) PL3373931T3 (enExample)
PT (1) PT3373931T (enExample)
RS (1) RS63837B1 (enExample)
RU (1) RU2727194C2 (enExample)
SI (1) SI3373931T1 (enExample)
SM (1) SMT202300062T1 (enExample)
WO (1) WO2017083756A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti
WO2018211323A1 (en) * 2017-05-17 2018-11-22 Oppilan Pharma Ltd. Hetercyclic compounds for the treatment of disease
EP3625230A1 (en) * 2017-05-17 2020-03-25 Oppilan Pharma Ltd. Prodrugs for the treatment of disease
GB201815018D0 (en) * 2018-09-14 2018-10-31 Univ Oxford Innovation Ltd Enantiomeric compounds
US12612401B2 (en) 2022-07-06 2026-04-28 Oppilan Pharma Limited Crystalline forms of an S1P receptor modulator
CN120835886A (zh) * 2023-01-13 2025-10-24 奥比兰制药有限公司 S1p受体调节剂的制备

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772597A (en) * 1983-10-14 1988-09-20 Pfizer Inc. 2-azacycloalkylthiopenem derivatives
WO2005032465A2 (en) 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists
GB0511684D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
RU2425832C2 (ru) * 2006-04-03 2011-08-10 Астеллас Фарма Инк. Гетеросоединение
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
RU2009127095A (ru) 2006-12-15 2011-01-20 Эбботт Лэборетриз (Us) Новые оксадиазольные соединения
WO2010117662A1 (en) 2009-03-30 2010-10-14 Exelixis, Inc. Modulators of s1p and methods of making and using
US9011494B2 (en) 2009-09-24 2015-04-21 Warsaw Orthopedic, Inc. Composite vertebral rod system and methods of use
HUE036391T2 (hu) 2009-11-13 2018-07-30 Celgene Int Ii Sarl Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások
JP5788507B2 (ja) * 2010-07-20 2015-09-30 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換3−フェニル−1,2,4−オキサジアゾール化合物
US20140288052A1 (en) 2011-10-20 2014-09-25 GlaxoSmithKline, LLC Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP6383418B2 (ja) 2013-11-27 2018-08-29 ジェネンテック, インコーポレイテッド 置換ベンズアミド及びその使用方法
HRP20221417T1 (hr) 2015-11-13 2023-02-03 Oppilan Pharma Ltd. Heterociklički spojevi za liječenje bolesti

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006131336A1 (en) * 2005-06-08 2006-12-14 Novartis Ag POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
US20100160369A1 (en) * 2008-12-04 2010-06-24 Exelixis, Inc. S1P1 Agonists and Methods of Making And Using

Also Published As

Publication number Publication date
HUE060594T2 (hu) 2023-03-28
KR102720397B1 (ko) 2024-10-21
BR112018009745A2 (pt) 2018-11-06
JP7174963B2 (ja) 2022-11-18
CN114149424B (zh) 2025-05-13
RU2018121416A3 (enExample) 2019-12-17
JP2023017862A (ja) 2023-02-07
KR20180095811A (ko) 2018-08-28
BR112018009745A8 (pt) 2019-02-26
DK3373931T3 (da) 2022-11-28
MX382092B (es) 2025-03-04
AU2021202945A1 (en) 2021-06-03
US20200325135A1 (en) 2020-10-15
SMT202300062T1 (it) 2023-03-17
RU2018121416A (ru) 2019-12-13
US20260092064A1 (en) 2026-04-02
US10683291B2 (en) 2020-06-16
JP7445325B2 (ja) 2024-03-07
WO2017083756A1 (en) 2017-05-18
US20190241556A1 (en) 2019-08-08
HRP20221417T1 (hr) 2023-02-03
IL259297B (en) 2022-11-01
US20220227767A1 (en) 2022-07-21
MX2018005987A (es) 2018-11-29
ES2932049T3 (es) 2023-01-09
JP2021191753A (ja) 2021-12-16
JP6933384B2 (ja) 2021-09-08
JP2018535261A (ja) 2018-11-29
EP3373931B1 (en) 2022-09-28
RU2727194C2 (ru) 2020-07-21
PT3373931T (pt) 2022-12-06
CN108463222B (zh) 2021-10-22
LT3373931T (lt) 2023-03-10
US20230339944A1 (en) 2023-10-26
CA3005236A1 (en) 2017-05-18
SI3373931T1 (sl) 2023-02-28
RS63837B1 (sr) 2023-01-31
EP4163281A1 (en) 2023-04-12
CN114149424A (zh) 2022-03-08
AU2016353348A1 (en) 2018-07-05
CN108463222A (zh) 2018-08-28
EP3373931A4 (en) 2019-04-03
PL3373931T3 (pl) 2023-02-06
EP4163281B1 (en) 2026-07-22
IL259297A (en) 2018-07-31
AU2021202945B2 (en) 2022-06-23
BR112018009745B1 (pt) 2023-09-26
CA3005236C (en) 2024-02-20
EP3373931A1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
US20260092064A1 (en) Heterocyclic compounds for the treatment of disease
JP7274478B2 (ja) 置換された-3H-イミダゾ[4,5-c]ピリジン及び1H-ピロロ[2,3-c]ピリジンシリーズの新規なエクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ-1(ENPP1)並びにがん免疫治療薬としてのインターフェロン遺伝子(STING)モジュレータのための刺激剤
AU2015370588B2 (en) Fused bicyclic compounds for the treatment of disease
MX2013006462A (es) Pirazolopirimidinas sustituidas como activadores de glucocerebrosidasa.
AU2020256301A1 (en) Fused bicyclic compounds for the treatment of disease
WO2018211323A1 (en) Hetercyclic compounds for the treatment of disease
US20200071327A1 (en) Prodrugs for the Treatment of Disease
US20210139492A1 (en) Furoquinolinediones as inhibitors of tdp2
CA2923175A1 (en) Liver x receptor (lxr) modulators
US20210332046A1 (en) Nicotinic acetylcholine receptor silent agonists
HK40070316A (en) Heterocyclic compounds for the treatment of disease
HK40070316B (en) Heterocyclic compounds for the treatment of disease
HK1260375B (en) Heterocyclic compounds for the treatment of disease
HK1260375A1 (en) Heterocyclic compounds for the treatment of disease